AI Telephone

Clinical Narrative: Patricia Davis

Patricia Davis is a 55-year-old female (Patient ID: PD-20240001) receiving care at Valley Medical Center under the primary care of Dr. Michael Thompson (Family Practice). She has no known drug allergies.

Active Diagnoses:

On February 7, 2024, Ms. Davis received a confirmed diagnosis of malignant neoplasm of the breast, Stage IIA, estrogen receptor-positive/progesterone receptor-positive/HER2-negative (ER+/PR+/HER2−). The diagnosis was confirmed by biopsy and pathology report. Supporting documentation on file includes a breast biopsy pathology report confirming invasive breast carcinoma, mammogram images associated with the diagnosis, and biopsy results. She also carries pre-existing active diagnoses of essential hypertension and hyperlipidemia.

Current Medications:

Dr. Thompson has prescribed lisinopril 10 mg orally once daily for hypertension and atorvastatin 20 mg orally once daily for hyperlipidemia. Both medications remain active.

Coordinated Care Plan:

On February 7, 2024, Dr. Thompson authored a comprehensive coordinated care plan for Ms. Davis's newly diagnosed breast cancer, encompassing oncology consultation, laboratory workup, imaging studies, and a surgical oncology second opinion. Insurance pre-authorization has been obtained for both the oncology and surgical oncology consultations. The plan includes the following scheduled activities:

1. Pre-consultation Laboratory Work – February 9, 2024, at 9:00 AM (30-minute appointment): Complete blood count (CBC), comprehensive metabolic panel (CMP), and tumor markers to be performed at Valley Medical Center – Hospital Laboratory, ordered by Dr. Thompson in preparation for the oncology consultation. Status: Booked.

2. Initial Oncology Consultation – February 12, 2024, at 2:00 PM (1-hour appointment): Dr. Jennifer Lee (Medical Oncology) at the Regional Cancer Center will see Ms. Davis for breast cancer treatment planning. The referral includes biopsy results, mammogram images, and the pathology report. Status: Booked.

3. Follow-up Mammogram and Breast MRI – February 13, 2024, at 10:30 AM (2-hour appointment): Both imaging studies will be performed at Valley Medical Center – Imaging Center for staging and treatment planning purposes. Status: Booked.

4. Surgical Oncology Second Opinion – February 14, 2024, at 3:00 PM (1-hour appointment): Dr. David Park (Surgical Oncology) at the Regional Cancer Center will provide a second opinion consultation for surgical planning. Insurance pre-authorization has been obtained. Status: Booked.

Insurance Coverage:

Ms. Davis has active insurance coverage with pre-authorization obtained for oncology consultations, including the surgical oncology second opinion.

Patricia Davis is a female patient born on June 15, 1968, with no known drug allergies. Her active problem list includes a Stage IIA malignant neoplasm of the breast, hypertension, and hyperlipidemia. To manage her cardiovascular conditions, she is currently prescribed a lisinopril 10 mg oral tablet daily for hypertension and an atorvastatin 20 mg oral tablet daily for hyperlipidemia.

In relation to her breast cancer diagnosis, active service requests have been placed for laboratory work (CBC, CMP, and tumor markers) and imaging (follow-up mammogram and breast MRI). Her care is being coordinated through several upcoming scheduled appointments. She is booked for pre-consultation lab work on October 27, 2023, at 09:00Z. She will then have an Initial Oncology Consultation with Dr. Jennifer Lee on October 30, 2023, at 14:00Z, followed by her imaging appointment for a mammogram and breast MRI on October 31, 2023, at 10:30Z. Finally, she is scheduled for a Surgical Oncology Second Opinion with Dr. David Park on November 1, 2023, at 15:00Z.

Patricia Davis, a 55-year-old female, is under the care of Regional Cancer Center for Stage IIA, ER+/PR+/HER2- breast cancer, diagnosed on January 1, 2023, by Dr. Michael Thompson. Her current medication regimen includes Lisinopril 10mg daily and Atorvastatin 20mg daily.

Patricia's upcoming medical schedule includes several appointments and procedures. On July 7, 2023, at 9:00 AM, she is scheduled for pre-consultation lab work, including a complete blood count, comprehensive metabolic panel, and tumor markers. This is followed by an initial consultation with oncologist Dr. Jennifer Lee on July 10, 2023, at 2:00 PM. On July 11, 2023, at 10:30 AM, Patricia is scheduled for follow-up imaging, including a mammogram and breast MRI. Additionally, she has a second opinion consultation with surgical oncologist Dr. David Park on July 12, 2023, at 3:00 PM.

These appointments and procedures are part of her comprehensive care plan for newly diagnosed breast cancer, ensuring a thorough evaluation and treatment strategy.

Patricia Davis is a 55-year-old female (DOB 1970-03-09). As of 2026-03-09, her active, confirmed problem list includes newly diagnosed breast cancer (SNOMED: malignant neoplasm of breast; ICD-10: C50.919), documented as Stage IIA with receptor profile ER-positive (ER+), PR-positive (PR+), and HER2-negative (HER2-) based on final laboratory observations dated 2026-03-09 (estrogen receptor status: positive; progesterone receptor status: positive; HER2 status: negative). Additional active, confirmed conditions recorded on 2026-03-09 include hypertension (ICD-10 I10) and hyperlipidemia (ICD-10 E78.5). Allergies: documented no known drug allergies (active, confirmed) recorded 2026-03-09.

Her primary care provider is Dr. Michael Thompson, Primary Care Provider, affiliated with Valley Medical Center. Oncology care involves Dr. Jennifer Lee (Medical Oncology) and Dr. David Park (Surgical Oncology), both affiliated with the Regional Cancer Center. A coordinated Breast cancer care plan (active; created 2026-03-09; authored by Dr. Michael Thompson) is in place and includes the above oncology team members (PCP, medical oncology, surgical oncology) and planned activities for consultation and diagnostic workup addressing the breast cancer diagnosis.

Current outpatient medication orders (active; authored 2026-03-09; ordered by Dr. Michael Thompson) include:

• Lisinopril 10 mg oral tablet: take 10 mg by mouth once daily (oral route).
• Atorvastatin 20 mg oral tablet: take 20 mg by mouth once daily (oral route).

Clinical documents available (DocumentReference; status current; dated 2026-03-09T09:00:00; author Dr. Michael Thompson; custodian Valley Medical Center) include: Breast biopsy results (PDF), breast pathology report (PDF), and mammogram imaging files (DICOM).

Active ordered services related to the breast cancer diagnosis (all authored 2026-03-09) include: (1) an initial medical oncology consultation for treatment planning, requested by the PCP role at Valley Medical Center and to be performed by medical oncology at the Regional Cancer Center, supported by the biopsy, pathology, and mammogram documents; (2) pre-consultation laboratory work including CBC with auto differential, comprehensive metabolic panel (CMP), and tumor markers, to be performed by the Hospital Laboratory; (3) follow-up breast imaging consisting of mammogram and breast MRI, to be performed by the Imaging Center; and (4) a second-opinion surgical oncology consultation, to be performed by surgical oncology at the Regional Cancer Center, also supported by the biopsy, pathology, and mammogram documents.

Scheduled appointments (all status booked, created 2026-03-09T09:00:00) are as follows:

• 2026-03-13 09:00–09:30: Pre-consultation lab work (CBC, CMP, tumor markers) at Hospital Laboratory – Phlebotomy.
• 2026-03-16 14:00–15:00: Initial oncology consultation with Dr. Jennifer Lee at Regional Cancer Center – Oncology Clinic for treatment planning.
• 2026-03-17 10:30–12:00: Follow-up mammogram and breast MRI at Imaging Center – Breast Imaging.
• 2026-03-18 15:00–16:00: Second-opinion surgical oncology consultation with Dr. David Park at Regional Cancer Center – Oncology Clinic.

Insurance coverage is active under subscriber/beneficiary Patricia Davis (subscriber ID SUB1234567) with payor Health Insurance Payor. A CoverageEligibilityResponse dated 2026-03-09T09:00:00 indicates outcome complete with disposition: “Insurance pre-authorization obtained for oncology consultations,” and the coverage is noted as in force.

Patricia Davis, a 55-year-old female born in 1969, presents with a medical history of Stage IIA breast cancer (ER+/PR+/HER2-), hypertension, and hyperlipidemia. She reports no known drug allergies. Her current medications include lisinopril 10mg daily for hypertension and atorvastatin 20mg daily for hyperlipidemia.

Dr. Michael Thompson has referred Patricia to Dr. Jennifer Lee at the Regional Cancer Center for oncology treatment planning. As part of her diagnostic workup, pre-consultation lab work including CBC, CMP, and tumor markers has been ordered, along with a follow-up mammogram and breast MRI.

Patricia's upcoming appointments include pre-consultation lab work scheduled for May 17, 2024, at 9:00 AM. She has an initial consultation with the oncologist, Dr. Jennifer Lee, at the Regional Cancer Center on May 20, 2024, at 2:00 PM. Additionally, a follow-up mammogram and breast MRI are scheduled for May 21, 2024, at 10:30 AM. A second opinion consultation with surgical oncologist Dr. David Park is scheduled for May 22, 2024, at 3:00 PM.

Patricia Davis is a female patient born in 1970 with no known drug allergies. She has an active, confirmed diagnosis of Stage IIA breast cancer. Recent biopsy and pathology reports from March 9, 2026, indicate that the tumor is estrogen receptor (ER) positive, progesterone receptor (PR) positive, and HER2 negative. Her medical history also includes active hypertension, for which she is prescribed lisinopril 10 mg by mouth once daily, and hyperlipidemia, for which she takes atorvastatin 20 mg by mouth once daily.

Her referring physician, Dr. Michael Thompson, has ordered several follow-up diagnostic tests and consultations to aid in her treatment planning. The following appointments have been booked:

• March 13, 2026, at 9:00 AM: Pre-consultation laboratory work (CBC, CMP, and tumor markers) at Hospital Lab - Phlebotomy.
• March 16, 2026, at 2:00 PM: Initial oncology consultation with medical oncologist Dr. Jennifer Lee at the Regional Cancer Center - Oncology Clinic.
• March 17, 2026, at 10:30 AM: Follow-up mammogram and breast MRI at the Imaging Center - Breast Imaging.
• March 18, 2026, at 3:00 PM: Surgical oncology second opinion consultation with Dr. David Park at the Regional Cancer Center - Oncology Clinic.

Insurance pre-authorization has been successfully obtained for her oncology consultations. Furthermore, her prior mammogram images, biopsy results, and pathology reports have been provided as supporting documentation for her upcoming specialty visits.

Patricia Davis is a 55-year-old female managed at Valley Medical Center. She has a confirmed, active diagnosis of invasive ductal carcinoma of the breast, staged at Stage IIA. Tumor marker assessment reveals the cancer is estrogen receptor-positive, progesterone receptor-positive, and HER2-negative (ER+/PR+/HER2-).

Her current active medications include lisinopril 10 mg orally once daily and atorvastatin 20 mg orally once daily.

Dr. Michael Thompson has placed an active referral to Dr. Jennifer Lee (medical oncology) at the Regional Cancer Center for management of her breast cancer, with supporting pathology and tumor marker information included.

Several follow-up appointments and diagnostic studies have been scheduled in relation to her breast cancer:

1. July 14, 2023, at 9:00 AM (30 minutes): Laboratory blood draw for a complete blood count (CBC) panel, comprehensive metabolic panel (CMP), and tumor markers panel, ordered in advance of her oncology visit.

2. July 17, 2023, at 2:00 PM (30 minutes): Follow-up medical oncology consultation with Dr. Jennifer Lee to review results and discuss ongoing cancer management.

3. July 18, 2023, at 10:30 AM (1 hour): Follow-up breast imaging, including a mammogram and MRI of the breast.

4. July 19, 2023, at 3:00 PM (30 minutes): Follow-up surgical oncology consultation with Dr. David Park to discuss surgical treatment options.

All appointments are currently booked and accepted by the patient and respective providers.

Supporting documentation on file includes a pathology study consisting of biopsy results, mammogram images, and a pathology report.

Patricia Davis is a female patient born in 1969 whose care is managed by Valley Medical Center (healthcare provider). Her identified care team includes Dr. Michael Thompson, MD (family practice/primary care physician, Valley Medical Center), Dr. Jennifer Lee, MD (medical oncology, Regional Cancer Center), and Dr. David Park, MD (surgical oncology).

She carries an active, confirmed diagnosis of malignant neoplasm of the breast (SNOMED: malignant neoplasm of breast; ICD-10-CM C50.919, malignant neoplasm of unspecified site of unspecified female breast), with onset dated 2024-01-15. The cancer is documented as Stage IIA (tumor staging) and described as ER-positive/PR-positive/HER2-negative (“Newly diagnosed breast cancer, Stage IIA.”). Supporting receptor status observations are final: estrogen receptor positive tumor, progesterone receptor positive tumor, and HER2/neu negative (human epidermal growth factor receptor 2 negative breast carcinoma). She also has active, confirmed hypertension (ICD-10-CM I10) and active, confirmed hyperlipidemia (ICD-10-CM E78.5). Allergy documentation indicates no known drug allergies (active, confirmed; recorded as medication category).

Current outpatient medication orders include lisinopril 10 mg oral tablet, status active, ordered by Dr. Michael Thompson, for hypertension, with instructions 10 mg by mouth once daily (frequency 1 every 1 day). She is also prescribed atorvastatin 20 mg oral tablet, status active, ordered by Dr. Michael Thompson, for hyperlipidemia, with instructions 20 mg by mouth once daily (frequency 1 every 1 day).

A coordinated oncology workup is in place under an active CarePlan titled “Breast Cancer Coordinated Care Plan”, authored by Dr. Michael Thompson, addressing Stage IIA breast cancer (ER+/PR+/HER2-). As part of this plan, an active referral/consultation ServiceRequest was placed for oncology treatment planning (“Referral to oncology for breast cancer treatment planning”), requested by Dr. Thompson with intended performer Dr. Jennifer Lee. The referral notes that insurance pre-authorization has been obtained for oncology consultations, and includes supporting documentation: biopsy results, mammogram images, and a pathology report. Insurance coverage is active with payor listed as Insurance Provider, and a ClaimResponse documents preauthorization approved for oncology consultations (outcome: complete; disposition: approved).

Additional active diagnostic ServiceRequests were ordered for pre-consultation and staging support, including complete blood count (CBC), comprehensive metabolic panel (CMP), and tumor marker measurement, as well as follow-up mammography and breast MRI. A separate active ServiceRequest was also placed for a second opinion consultation with surgical oncologist Dr. David Park.

Scheduled appointments (all status booked) include:

• Pre-consultation lab work (CBC, CMP, tumor markers) at Valley Medical Center – Hospital Lab on 2024-01-19 from 09:00 to 09:30 UTC (30 minutes), with Patricia Davis listed as an accepted required participant.
• Initial oncology consultation at Regional Cancer Center with Dr. Jennifer Lee on 2024-01-22 from 14:00 to 15:00 UTC (60 minutes), for breast cancer treatment planning; patient, oncologist, and the Regional Cancer Center are all accepted required participants.
• Follow-up imaging (follow-up mammogram and breast MRI) on 2024-01-23 from 10:30 to 12:30 UTC (120 minutes), with the patient as an accepted required participant.
• Second opinion surgical oncology consultation with Dr. David Park on 2024-01-24 from 15:00 to 16:00 UTC (60 minutes), with both patient and surgeon listed as accepted required participants.

Relevant clinical documents on file (current) include: a tissue pathology biopsy report (“Biopsy results”) describing a recent breast biopsy confirming malignancy; mammogram images; and a surgical pathology report noting ER+/PR+/HER2- receptor status and staging.